Immunoexpression of GLUT-1 and angiogenic index in pleomorphic adenomas, adenoid cystic carcinomas, and mucoepidermoid carcinomas of the salivary glands

Souza, Lélia Batista de; Oliveira, Lucileide Castro De; Nonaka, Cassiano Francisco Weege; Lopes, Maria Luiza Diniz de Sousa; Pinto, Leão Pereira; Queiroz, Lélia Maria Guedes

doi:10.1007/s00405-017-4530-y

Cited by 13 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GLUT-1 expression was not detected in normal salivary gland tissues but wasfound mainly in the cytoplasm of pleomorphic adenomas (PAs), adenoid cystic carcinomas (ACCs), and mucoepidermoid carcinomas (MECs) of the salivary glands by de Souza et al (2017) [59]. Some cases showed membrane staining only in focal areas.…”

Section: Introductionmentioning

confidence: 99%

Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…MVC was performed as described by de Souza, et al [10] . Tissue sections were examined by light microscopy at ×200 magni cation and ten areas showing the highest vascularization were identi ed.…”

Section: Immunostaining Assessment and Statistical Analysismentioning

confidence: 99%

APLN/APJ may act as a Novel Diagnostic Marker and a Potential Therapeutic Target for Infantile Hemangioma

Chen

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Infantile hemangioma (IH) is the most common benign tumor in children with the characteristics of endothelial cells (ECs) proliferation and natural regression, and recent evidence shows that abnormal proliferation of ECs of IH is closely related to Apelin and Apelin receptor (APLN/APJ). This study aimed to evaluate and compare the immunoexpression of APLN/APJ and angiogenic index about IH, and establish the specificity with the histomorphology. Methods: 3 IHs（proliferating）, 3 IHs（involuting）, 3 congenital hemangiomas (CHs), 3 pyogenic granulomas (PGs), 3 capillary malformations (CMs), and 3 venous malformations (VMs) were submitted to morphological and immunohistochemical analysis. APLN/APJ expression was semi-quantitatively evaluated, and the angiogenic index was assessed by microvessel counts (MVC). Results: Higher APLN/APJ immunoexpression was observed in the proliferating phase of IHs compared to the involuting phase of IHs (p ＜ 0.05). Compared with CD31, APJ/APLN only expressed in proliferating and partial involuting phases of IHs; Compared with GLUT-1, APLN/APJ was expressed specifically in IH vascular ECs. APLN/APJ expression and angiogenic index significantly correlated in the IHs study. Conclusions: our research suggests that the expression of APLN/APJ in IH is specific, and may reflect the influence on the initiation and regulation of IH, which can be used as a new specific antibody for clinical pathological diagnosis and a new target for clinical treatment.

show abstract

“…When there is perineural invasion, lymph node involvement, advanced high-grade tumors, positive margins after resection, and extra-glandular extension, adjuvant radiotherapy is recommended [ 12 , 13 ]. Combined chemoradiotherapy showed better regional control, but no difference was found between the overall survival rate and patients receiving radiotherapy alone [ 14 ]. Systemic therapies have shown no evidence to improve survival; therefore, they should be used as palliative treatment for cancer-related symptoms relief or in rapid progression of the disease [ 15 - 17 ].…”

Section: Introductionmentioning

confidence: 99%

Advances in the Treatment of Mucoepidermoid Carcinoma

2022

View full text Add to dashboard Cite

Mucoepidermoid carcinoma (MEC) represents 10-15% of salivary neoplasms. Due to their low incidence, it is challenging to conduct clinical trials and develop treatment guidelines. Although surgery is the most common approach for a resectable tumor, various treatment options such as chemotherapy, radiotherapy, and immunotherapy have been investigated. There is a need to implement a standardized treatment protocol to effectively manage MEC as it is a common histological subtype. Furthermore, it has become essential to assess chromosomal and genetic abnormalities recently identified with MEC, including alterations of CDKN2A , TP53 , CDKN2B , BAP1 , etc. These mutations are involved in the transformation of low-grade tumors to high-grade tumors, presenting a vital tool for evaluating the aggressive behavior of this carcinoma. Detailed immunohistochemical and translocation studies can help develop targeted therapies and monitor treatment response. Therefore, biomarker-driven research will immensely improve the outcome, especially in advanced cases. Based on thorough histology and chromosomal translocations, a more personalized treatment plan can improve the overall disease outcome. The purpose of this article is to elaborate on the current treatment advancements, particularly chemotherapy and targeted therapy, as an effective treatment modality for the management of MEC and highlight the comparison with traditional treatment approaches.

show abstract

Immunoexpression of GLUT-1 and angiogenic index in pleomorphic adenomas, adenoid cystic carcinomas, and mucoepidermoid carcinomas of the salivary glands

Cited by 13 publications

References 38 publications

Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer

Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer

APLN/APJ may act as a Novel Diagnostic Marker and a Potential Therapeutic Target for Infantile Hemangioma

Advances in the Treatment of Mucoepidermoid Carcinoma

Contact Info

Product

Resources

About